May 26, 2024

The Rising Immune System Care Is Driving Advancements In Immunology

The immunology market is rapidly expanding as focus on preventive healthcare and immune system care rises globally. Immunology involves study and treatment of disorders related to immunity and focuses on developing biological products to treat various immune mediated diseases. Key products in immunology market include monoclonal antibodies, vaccines, blood & blood products and recombinant proteins which find wide applications in treatment of cancer, autoimmune disorders, infectious diseases and other disorders. The global Immunology Market is estimated to be valued at US$ 123418.19 Bn in 2024 and is expected to exhibit a CAGR of 17% over the forecast period between 2024 to 2030.

The Immunology Market deals with diverse range of products that enhances immunity and treats various diseases when immunity is compromised. Monoclonal antibodies are recombinant antibodies that target specific cells or proteins of the immune system. They are major blockbuster products utilized for treatment of cancer, arthritis and other autoimmune conditions. Vaccines prevent infections by inducing adaptive immunity and are crucial for public health programs worldwide. Blood products are utilized for replacement therapy in conditions like anemia, hemophilia and thrombocytopenia. Recombinant proteins simulate human proteins of the immune system and regulate its functions. With growing prevalence of immune disorders and rising healthcare expenditure, the demand for immunomodulating therapies have increased tremendously providing a fillip to the immunology market.

Key Takeaways
Key players operating in the immunology market are Production I.G, Inc., Studio Ghibli, Inc., Pierrot Co., Ltd., Sunrise Inc., Toei Animation Co., Ltd., BONES INC, Kyoto Animation Co.,Ltd., MADHOUSE Inc., Manglobe Inc., and PAWORKS Co., Ltd. These players dominate the market with their strong portfolio of immunotherapies and wide geographical presence across major markets. Furthermore, their investment in research and development has led to approval and launch of novel biologics expanding treatment opportunities.

The growing burden of immune disorders and various types of cancers globally is a major factor driving demand for immunotherapies. According to WHO, cancer incidence is projected to increase by over 70% in next two decades putting immense pressure on healthcare systems. Similarly, autoimmune disorders like rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease have high and rising prevalence worldwide necessitating development of advanced immunomodulators.

With increasing access to healthcare in developing economies and expanding footprints of key pharma companies, the immunology market is witnessing robust growth in Asian and Latin American countries. Supportive regulatory environment and amendments to intellectual property guidelines have opened up these markets for global innovators. Investments in medical infrastructure, healthcare modernization programs and wider health insurance penetration are further stimulating the demand for immunotherapies in emerging nations providing vast future opportunities.

Market Key Trends
One of the major trends observed in Immunology Market Size Is the rising focus on development of novel biologics with enhanced clinical profile. With advances in biotechnology and omics, next generation immunotherapies like antibody drug conjugates, bi-specific antibodies and cell and gene therapies are entering the markets. These new compounds act as potent immunomodulators and have improved efficacy and safety over existing immunotherapies. Their approvals and commercialization will provide next phase of growth drivers in immunology industry. Also, greater insights into mechanisms of immune system attained through immunology research are leading to identification of new targets and pathways opening up scope for various pipeline drugs which will expand the market in coming years.

Porter’s Analysis
Threat of new entrants: High capital investments require for research and development acts as a barrier. Bargaining power of buyers: Large number of buyers are present in market it increase the bargaining power of buyers. Bargaining power of suppliers: Due presence of many supplier it decreases the bargaining power of suppliers. Threat of new substitutes: Threat is low as there is no close substitute of existing immunological products. Competitive rivalry: Fierce completion exist between large number of players due to high growth opportunities in the market.

Porter’s Analysis
Threat of new entrants: High capital investments require for research and development acts as a barrier. Bargaining power of buyers: Large number of buyers are present in market it increase the bargaining power of buyers. Bargaining power of suppliers: Due presence of many supplier it decreases the bargaining power of suppliers. Threat of new substitutes: Threat is low as there is no close substitute of existing immunological products. Competitive rivalry: Fierce completion exist between large number of players due to high growth opportunities in the market.

Geographical Regions
North America region accounted for largest share in global immunology market in terms of revenue. Many key players in region and presence of advance healthcare infrastructure stimulate large revenue generation.

Asia Pacific region exhibits fastest growth rate during forecast period. Increasing healthcare spending, large patient population along with rising awareness regarding immunological disorders fuel market growth tremendously in region. Improving healthcare infrastructure and healthcare reforms by various governments in countries like India and China projected to drive Asia Pacific immunology market.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it